Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free DTIL Stock Alerts

Precision BioSciences (DTIL) Financials

Precision BioSciences logo
$7.87 -0.45 (-5.41%)
Closing price 04:00 PM Eastern
Extended Trading
$7.86 -0.01 (-0.13%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Precision BioSciences

Annual Income Statements for Precision BioSciences

This table shows Precision BioSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -93 -109 -31 -112 -61 7.17 -46
Consolidated Net Income / (Loss)		 -99 -108 -31 -112 -61 7.17 -46
Net Income / (Loss) Continuing Operations		 -99 -108 -31 -73 -43 7.17 -47
Total Pre-Tax Income 		-93 -109 -31 -73 -43 7.17 -46
Total Operating Income		 -87 -110 -39 -62 -44 -26 -52
Total Gross Profit		 22 24 116 25 49 69 34
Total Revenue		 22 24 116 25 49 69 34
Operating Revenue		 22 24 116 25 49 69 34
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 109 134 155 98 92 95 87
Selling, General & Admin Expense		 27 36 40 41 39 35 32
Research & Development Expense		 82 98 115 46 53 60 54
Impairment Charge		 - - 0.00 11 0.00 0.00 0.04
Other Special Charges / (Income)		 - - 0.03 0.03 - - 0.42
Total Other Income / (Expense), net		 -5.67 0.82 8.80 0.27 1.21 33 6.00
Interest Expense		 0.18 0.00 0.13 1.11 2.23 1.78 1.42
Interest & Investment Income		 4.27 0.82 6.38 1.89 2.76 5.68 -1.05
Other Income / (Expense), net		 -9.76 0.00 2.56 -0.51 0.68 29 8.46
Net Income / (Loss) Discontinued Operations		 - - - -39 -19 0.00 0.89
Basic Earnings per Share		 ($2.21) ($2.09) ($0.52) ($38.10) ($15.96) $1.05 ($3.56)
Weighted Average Basic Shares Outstanding		 41.99M 52.03M 58.69M 2.93M 3.84M 6.83M 12.83M
Diluted Earnings per Share		 ($2.21) ($2.09) ($0.52) ($38.10) ($15.96) $1.04 ($3.56)
Weighted Average Diluted Shares Outstanding		 41.99M 52.03M 58.69M 2.93M 3.84M 6.88M 12.83M
Weighted Average Basic & Diluted Shares Outstanding		 41.99M 52.03M 58.69M 111.30M 6.92M 10.48M 24.73M

Quarterly Income Statements for Precision BioSciences

This table shows Precision BioSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -8.08 -16 8.59 33 -16 -18 -21 -24 -22 20 -18
Consolidated Net Income / (Loss)		 -8.08 -16 8.59 33 -16 -18 -21 -24 -22 20 -18
Net Income / (Loss) Continuing Operations		 -12 -13 8.59 33 -16 -18 -21 -24 -22 19 -18
Total Pre-Tax Income 		-12 -13 8.59 33 -16 -18 -21 -23 -22 20 -18
Total Operating Income		 -12 -15 -4.19 24 -21 -25 -22 -22 -21 13 -9.08
Total Gross Profit		 13 7.04 18 50 0.58 0.64 0.03 0.02 0.01 34 11
Total Revenue		 13 7.04 18 50 0.58 0.64 0.03 0.02 0.01 34 11
Operating Revenue		 13 7.04 18 50 0.58 0.64 0.03 0.02 0.01 34 11
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 25 22 22 26 22 25 22 22 21 22 20
Selling, General & Admin Expense		 9.63 8.54 8.43 8.53 8.77 9.58 8.55 9.13 7.33 7.23 6.80
Research & Development Expense		 16 13 13 17 13 16 14 13 13 14 13
Other Special Charges / (Income)		 0.00 - - 0.19 0.00 - 0.01 0.03 -0.00 - -0.00
Total Other Income / (Expense), net		 0.26 1.45 13 8.79 4.85 6.91 1.56 -1.62 -1.11 7.18 -9.37
Interest Expense		 0.58 0.58 0.57 0.56 0.26 0.39 0.35 0.36 0.36 0.35 0.31
Interest & Investment Income		 0.52 0.96 3.38 0.89 0.89 0.52 2.67 0.45 0.44 -4.60 1.00
Other Income / (Expense), net		 0.31 1.07 9.97 8.46 4.22 6.78 -0.76 -1.71 -1.18 12 -10
Basic Earnings per Share		 ($2.10) ($4.24) $1.70 $4.70 ($2.25) ($2.60) ($2.21) ($2.13) ($1.84) $1.57 ($0.75)
Weighted Average Basic Shares Outstanding		 3.84M 3.84M 5.06M 6.97M 7.29M 6.83M 9.29M 11.05M 11.82M 12.83M 24.63M
Diluted Earnings per Share		 ($2.10) ($4.24) $1.70 $4.67 ($2.25) ($2.60) ($2.21) ($2.13) ($1.84) $1.57 ($0.75)
Weighted Average Diluted Shares Outstanding		 3.84M 3.84M 5.06M 7.01M 7.29M 6.88M 9.29M 11.05M 11.82M 12.83M 24.63M
Weighted Average Basic & Diluted Shares Outstanding		 118.94M 6.92M 6.93M 7.23M 7.67M 10.48M 11.09M 11.79M 13.26M 24.73M 25.80M

Annual Cash Flow Statements for Precision BioSciences

This table details how cash moves in and out of Precision BioSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 78 -91 54 46 -73 -8.21 29
Net Cash From Operating Activities		 -71 -87 -11 -46 -84 -58 -66
Net Cash From Continuing Operating Activities		 -71 -87 -31 -46 -85 -58 -66
Net Income / (Loss) Continuing Operations		 -93 -109 -31 -112 -61 7.17 -46
Consolidated Net Income / (Loss)		 -93 -109 -31 -112 -61 7.17 -46
Depreciation Expense		 5.32 8.78 8.98 7.80 6.82 3.40 1.47
Amortization Expense		 0.00 1.04 1.26 1.15 1.29 0.73 0.79
Non-Cash Adjustments To Reconcile Net Income		 18 14 -22 31 9.94 -5.47 3.54
Changes in Operating Assets and Liabilities, net		 -1.34 -2.01 12 26 -41 -64 -26
Net Cash From Investing Activities		 -25 -5.03 -5.80 -3.32 5.83 -0.22 -0.63
Net Cash From Continuing Investing Activities		 -25 -5.03 -5.80 -3.32 5.83 -0.22 -0.63
Purchase of Property, Plant & Equipment		 -25 -5.03 -5.05 -3.32 -1.96 -0.25 -0.09
Sale of Property, Plant & Equipment		 - - - 0.00 0.11 0.06 0.07
Other Investing Activities, net		 - 0.00 -0.75 0.00 -0.32 -0.03 -0.62
Net Cash From Financing Activities		 173 1.33 71 95 5.39 50 95
Net Cash From Continuing Financing Activities		 173 1.33 71 95 5.39 50 95
Repayment of Debt		 - 0.00 -2.51 0.00 0.00 -23 0.00
Issuance of Debt		 40 0.00 4.97 20 0.00 22 0.00
Issuance of Common Equity		 135 0.00 60 74 4.99 50 95
Other Financing Activities, net		 1.26 1.33 7.59 0.84 0.40 0.25 0.22
Cash Interest Paid		 - - 0.07 0.82 2.02 1.74 1.36

Quarterly Cash Flow Statements for Precision BioSciences

This table details how cash moves in and out of Precision BioSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -16 -5.55 21 -14 -2.24 -13 -8.68 -15 -14 66 -11
Net Cash From Operating Activities		 -23 -8.42 -19 -15 -5.91 -19 -19 -20 -15 -11 -12
Net Cash From Continuing Operating Activities		 -23 -9.06 -19 -15 -5.91 -19 -19 -20 -15 -12 -12
Net Income / (Loss) Continuing Operations		 -8.08 -16 8.59 33 -16 -18 -21 -24 -22 20 -18
Consolidated Net Income / (Loss)		 -8.08 -16 8.59 33 -16 -18 -21 -24 -22 20 -18
Depreciation Expense		 1.62 1.28 1.14 1.09 0.72 0.45 0.40 0.38 0.35 0.35 0.30
Amortization Expense		 0.34 0.13 0.40 0.15 0.04 0.14 0.17 0.15 0.11 0.36 0.46
Non-Cash Adjustments To Reconcile Net Income		 -4.30 2.86 -0.02 3.64 14 -23 4.18 6.40 2.98 -8.90 12
Changes in Operating Assets and Liabilities, net		 -13 2.96 -29 -52 -4.11 21 -3.23 -3.69 3.06 -23 -5.86
Net Cash From Investing Activities		 7.56 0.04 -0.03 -0.03 -0.06 -0.10 -0.31 -0.01 0.02 -0.33 -0.11
Net Cash From Continuing Investing Activities		 7.56 0.04 -0.03 -0.03 -0.06 -0.10 -0.31 -0.01 0.02 -0.33 -0.11
Purchase of Property, Plant & Equipment		 -0.39 0.03 -0.09 -0.03 -0.04 -0.10 -0.06 -0.00 - -0.02 -0.02
Sale of Property, Plant & Equipment		 - 0.04 0.06 - - - 0.00 0.01 0.02 0.04 0.00
Other Investing Activities, net		 -0.05 -0.02 0.00 - -0.03 - -0.25 -0.02 - -0.35 -0.10
Net Cash From Financing Activities		 -0.03 2.83 40 0.70 3.73 5.92 11 5.30 1.66 78 0.75
Net Cash From Continuing Financing Activities		 -0.03 2.83 40 0.70 3.73 5.92 11 5.30 1.66 78 0.75
Issuance of Common Equity		 -0.14 2.83 40 0.70 3.61 5.94 11 5.30 1.58 78 0.66
Other Financing Activities, net		 0.10 0.00 0.11 - 0.14 - 0.14 - 0.08 - 0.08
Cash Interest Paid		 0.52 0.53 0.53 0.53 0.31 0.37 0.34 0.35 0.35 0.33 0.30

Annual Balance Sheets for Precision BioSciences

This table presents Precision BioSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 139 235 150 211 238 160 136 154
Total Current Assets		 116 194 106 162 199 136 95 119
Cash & Equivalents		 103 181 90 144 190 117 86 111
Short-Term Investments		 - - - - - 0.00 0.41 4.76
Accounts Receivable		 0.52 0.97 10 0.49 0.72 0.90 0.23 0.00
Prepaid Expenses		 8.91 9.50 5.76 17 6.03 5.98 6.44 3.11
Other Current Assets		 3.05 2.32 0.00 0.17 1.23 0.91 2.01 0.05
Plant, Property, & Equipment, net		 21 40 35 25 12 6.34 3.09 1.43
Total Noncurrent Assets		 1.78 1.99 9.50 25 27 17 38 34
Long-Term Investments		 - - - 6.84 4.75 3.21 3.21 0.74
Intangible Assets		 1.47 1.43 1.37 2.05 0.73 0.40 0.62 1.17
Other Noncurrent Operating Assets		 0.31 0.56 8.13 8.82 2.19 8.49 30 32
Total Liabilities & Shareholders' Equity		 139 235 150 211 238 160 136 154
Total Liabilities		 99 97 106 120 178 141 80 62
Total Current Liabilities		 14 27 43 36 60 50 15 8.91
Accounts Payable		 2.22 2.04 0.79 1.14 0.65 2.97 1.31 0.30
Accrued Expenses		 2.46 2.40 3.27 4.03 1.83 1.56 2.02 1.71
Current Employee Benefit Liabilities		 0.97 4.43 5.75 6.77 5.10 4.98 5.18 4.75
Other Current Liabilities		 - 1.58 2.79 2.80 2.42 3.52 2.31 2.16
Total Noncurrent Liabilities		 85 70 63 84 118 91 65 53
Long-Term Debt		 - - - 2.48 22 0.00 22 22
Other Noncurrent Operating Liabilities		 - 0.00 8.98 15 11 18 19 31
Total Equity & Noncontrolling Interests		 40 138 44 91 60 19 56 92
Total Preferred & Common Equity		 40 138 44 91 60 19 56 92
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 40 138 44 91 60 19 56 92
Common Stock		 126 316 331 409 490 509 540 621
Retained Earnings		 -85 -177 -286 -317 -428 -490 -482 -528
Treasury Stock		 -0.95 -0.95 -0.95 -0.95 -0.95 -0.95 -0.95 -0.95

Quarterly Balance Sheets for Precision BioSciences

This table presents Precision BioSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 164 185 166 153 124 109 94 144
Total Current Assets		 146 161 144 111 82 70 52 109
Cash & Equivalents		 122 138 124 99 77 62 45 99
Short-Term Investments		 - - - 2.45 0.00 0.00 0.00 1.81
Accounts Receivable		 3.51 0.39 0.21 0.19 0.00 0.00 0.00 4.00
Prepaid Expenses		 8.08 9.25 5.67 7.11 4.59 7.45 5.86 3.50
Other Current Assets		 0.35 1.87 2.34 2.02 0.29 0.57 0.97 0.01
Plant, Property, & Equipment, net		 8.74 5.29 4.23 3.56 2.72 2.36 2.03 1.18
Total Noncurrent Assets		 9.75 19 18 39 40 36 40 34
Long-Term Investments		 1.81 3.21 3.21 3.21 3.21 0.74 0.74 0.74
Intangible Assets		 0.98 0.39 0.38 0.39 0.61 0.61 0.99 1.13
Other Noncurrent Operating Assets		 1.31 8.22 7.92 30 30 29 33 32
Total Liabilities & Shareholders' Equity		 164 185 166 153 124 109 94 144
Total Liabilities		 135 148 91 88 75 75 77 68
Total Current Liabilities		 51 33 33 12 12 14 15 7.76
Accounts Payable		 0.53 1.14 1.14 0.96 0.92 1.12 1.34 0.94
Accrued Expenses		 1.47 0.66 1.87 3.29 1.31 0.99 1.30 3.26
Current Employee Benefit Liabilities		 3.83 1.22 2.48 3.59 1.29 2.45 3.16 1.14
Other Current Liabilities		 3.34 3.95 3.14 2.66 2.26 2.13 2.07 2.42
Total Noncurrent Liabilities		 85 114 58 76 63 61 62 60
Long-Term Debt		 0.00 - - 22 22 22 22 22
Other Noncurrent Operating Liabilities		 11 39 31 28 20 19 20 38
Total Equity & Noncontrolling Interests		 29 37 75 65 49 34 17 76
Total Preferred & Common Equity		 29 37 75 65 49 34 17 76
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 29 37 75 65 49 34 17 76
Common Stock		 503 519 524 531 553 562 566 624
Retained Earnings		 -473 -481 -448 -465 -503 -527 -548 -547
Treasury Stock		 -0.95 -0.95 -0.95 -0.95 -0.95 -0.95 -0.95 -0.95

Annual Metrics And Ratios for Precision BioSciences

This table displays calculated financial ratios and metrics derived from Precision BioSciences' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 50,787,317.00 52,480,469.00 60,767,307.00 110,958,955.00 118,935,191.00 7,671,059.00 13,256,751.00
DEI Adjusted Shares Outstanding		 1,692,911.00 1,749,349.00 2,025,577.00 3,698,632.00 3,964,506.00 7,671,059.00 13,256,751.00
DEI Earnings Per Adjusted Shares Outstanding		 -54.86 -62.31 -15.11 -30.18 -15.47 0.93 -3.45
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 9.21% 375.72% -78.28% 94.15% 40.98% -50.12%
EBITDA Growth		 0.00% -9.13% 73.43% -102.70% 35.14% 121.18% -659.76%
EBIT Growth		 0.00% -13.27% 66.47% -70.60% 31.47% 107.60% -1,435.93%
NOPAT Growth		 0.00% -25.94% 64.15% -58.24% 29.81% 14.55% -39.53%
Net Income Growth		 0.00% -9.78% 71.71% -264.80% 45.07% 111.69% -737.98%
EPS Growth		 0.00% 5.43% 75.12% -264.80% 45.07% 106.52% -442.31%
Operating Cash Flow Growth		 0.00% -23.05% 87.58% -321.57% -83.84% 30.52% -12.66%
Free Cash Flow Firm Growth		 0.00% 0.00% 78.30% 223.86% -476.15% -23.70% 52.05%
Invested Capital Growth		 0.00% -6.58% -25.31% -111.73% 36.79% 87.38% 82.53%
Revenue Q/Q Growth		 0.00% 0.00% -2.12% 20.44% -6.81% -8.52% 4,808.88%
EBITDA Q/Q Growth		 0.00% -1,192.94% -21.27% 42.14% -203.47% -40.62% 50.82%
EBIT Q/Q Growth		 0.00% 0.00% -14.59% 38.59% -110.16% -56.48% 49.43%
NOPAT Q/Q Growth		 0.00% 0.00% -22.54% 39.09% -123.27% -61.43% 41.74%
Net Income Q/Q Growth		 0.00% 0.00% 1.36% -5.83% 16.59% -16.89% 45.31%
EPS Q/Q Growth		 0.00% 0.00% 1.89% -5.83% 16.59% -11.86% 49.65%
Operating Cash Flow Q/Q Growth		 0.00% 7.52% -1,639.26% 3.86% 13.76% -21.29% 10.14%
Free Cash Flow Firm Q/Q Growth		 0.00% -629.62% -196.06% 197.62% -45.92% -30.11% 39.05%
Invested Capital Q/Q Growth		 15.66% -12.52% 0.92% -10.87% -7.23% 39.85% 70.69%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -412.11% -411.84% -23.01% -214.65% -71.71% 10.77% -120.91%
Operating Margin		 -392.14% -452.25% -34.08% -248.26% -89.76% -38.08% -152.19%
EBIT Margin		 -436.02% -452.25% -31.87% -250.29% -88.35% 4.76% -127.50%
Profit (Net Income) Margin		 -443.16% -445.48% -26.49% -444.80% -125.84% 10.43% -133.45%
Tax Burden Percent		 106.11% 99.25% 100.09% 153.12% 144.19% 100.00% 99.07%
Interest Burden Percent		 95.79% 99.25% 83.04% 116.06% 98.78% 219.17% 105.65%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -110.56% -118.40% -45.14% -147.28% -154.66% 19.05% -61.52%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -51.87% -57.00% -20.36% -27.94% -21.64% 2.21% -30.04%
Return on Assets (ROA)		 -52.72% -56.14% -16.92% -49.65% -30.82% 4.84% -31.45%
Return on Common Equity (ROCE)		 -110.56% -118.40% -45.14% -147.28% -154.66% 19.05% -61.52%
Return on Equity Simple (ROE_SIMPLE)		 -71.25% -243.52% -33.57% -184.73% -325.11% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -61 -77 -28 -44 -31 -26 -37
NOPAT Margin		 -274.50% -316.57% -23.86% -173.78% -62.83% -38.08% -106.54%
Net Nonoperating Expense Percent (NNEP)		 -20.74% -23.13% -2.56% -41.37% -22.27% 41.41% -11.53%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -74.18% -33.24% -31.84%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 121.53% 148.45% 34.34% 164.49% 80.22% 51.38% 94.09%
R&D to Revenue		 370.61% 403.79% 99.75% 183.77% 109.54% 86.70% 158.10%
Operating Expenses to Revenue		 492.14% 552.25% 134.11% 391.59% 189.76% 138.08% 253.53%
Earnings before Interest and Taxes (EBIT)		 -97 -110 -37 -63 -43 3.27 -44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -92 -100 -27 -54 -35 7.40 -41
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 5.10 9.85 4.93 2.18 2.30 0.52 0.60
Price to Tangible Book Value (P/TBV)		 5.15 10.17 5.05 2.21 2.35 0.52 0.61
Price to Revenue (P/Rev)		 31.72 18.02 3.89 5.26 0.89 0.43 1.61
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 4.08 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 24.52% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 23.59 14.33 2.61 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.03 0.37 1.19 0.40 0.24
Long-Term Debt to Equity		 0.00 0.00 0.03 0.37 0.00 0.40 0.24
Financial Leverage		 -1.31 -1.48 -1.75 -2.17 -3.48 -2.14 -1.08
Leverage Ratio		 2.10 2.11 2.67 2.97 5.02 3.94 1.96
Compound Leverage Factor		 2.01 2.09 2.21 3.44 4.96 8.63 2.07
Debt to Total Capital		 0.00% 0.00% 2.65% 26.89% 54.30% 28.36% 19.54%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 54.30% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 2.65% 26.89% 0.00% 28.36% 19.54%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 97.35% 73.11% 45.70% 71.64% 80.46%
Debt to EBITDA		 0.00 0.00 -0.09 -0.41 -0.64 3.02 -0.54
Net Debt to EBITDA		 0.00 0.00 5.57 3.19 2.79 -9.08 2.27
Long-Term Debt to EBITDA		 0.00 0.00 -0.09 -0.41 0.00 3.02 -0.54
Debt to NOPAT		 0.00 0.00 -0.09 -0.51 -0.73 -0.85 -0.61
Net Debt to NOPAT		 0.00 0.00 5.37 3.95 3.18 2.57 2.57
Long-Term Debt to NOPAT		 0.00 0.00 -0.09 -0.51 0.00 -0.85 -0.61
Altman Z-Score		 2.90 -1.93 0.83 -2.13 -4.04 -3.45 -4.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 7.19 2.46 4.50 3.34 2.73 6.34 13.32
Quick Ratio		 6.75 2.33 4.01 3.19 2.59 5.78 12.97
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -74 -16 20 -75 -93 -44
Operating Cash Flow to CapEx		 -287.91% -1,736.95% -214.78% -1,378.52% -4,546.70% -30,760.53% -346,542.11%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -121.80 17.92 -33.59 -52.00 -31.24
Operating Cash Flow to Interest Expense		 -390.19 0.00 -82.22 -41.18 -37.72 -32.80 -46.30
Operating Cash Flow Less CapEx to Interest Expense		 -525.72 0.00 -120.50 -44.17 -38.55 -32.90 -46.32
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.12 0.13 0.64 0.11 0.24 0.46 0.24
Accounts Receivable Turnover		 29.89 4.43 22.03 41.55 60.12 121.59 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.73 0.65 3.84 1.36 5.37 14.57 15.18
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 12.21 82.40 16.57 8.78 6.07 3.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 12.21 82.40 16.57 8.78 6.07 3.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -43 -45 -57 -120 -76 -9.60 -1.68
Invested Capital Turnover		 -0.52 -0.55 -2.26 -0.28 -0.50 -1.60 -6.08
Increase / (Decrease) in Invested Capital		 0.00 -2.80 -11 -64 44 66 7.92
Enterprise Value (EV)		 525 348 302 -40 -54 -38 -39
Market Capitalization		 705 438 450 132 43 29 55
Book Value per Share		 $2.72 $0.85 $1.50 $0.54 $0.16 $7.35 $6.96
Tangible Book Value per Share		 $2.70 $0.82 $1.47 $0.54 $0.16 $7.27 $6.87
Total Capital		 138 44 94 83 41 79 115
Total Debt		 0.00 0.00 2.48 22 22 22 22
Total Long-Term Debt		 0.00 0.00 2.48 22 0.00 22 22
Net Debt		 -181 -90 -148 -172 -97 -67 -94
Capital Expenditures (CapEx)		 25 5.03 5.05 3.32 1.85 0.19 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -14 -27 -18 -50 -7.89 -6.30 -5.76
Debt-free Net Working Capital (DFNWC)		 167 63 126 139 109 80 110
Net Working Capital (NWC)		 167 63 126 139 86 80 110
Net Nonoperating Expense (NNE)		 38 31 3.04 68 31 -33 9.22
Net Nonoperating Obligations (NNO)		 -181 -90 -148 -181 -95 -66 -94
Total Depreciation and Amortization (D&A)		 5.32 9.81 10 8.94 8.11 4.13 2.26
Debt-free, Cash-free Net Working Capital to Revenue		 -63.61% -111.44% -15.48% -199.76% -16.20% -9.18% -16.80%
Debt-free Net Working Capital to Revenue		 749.80% 258.33% 108.87% 555.59% 223.25% 116.47% 320.53%
Net Working Capital to Revenue		 749.80% 258.33% 108.87% 555.59% 177.26% 116.47% 320.53%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($62.70) ($15.60) ($38.10) ($15.96) $1.05 ($3.56)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.90M 2.03M 2.93M 3.84M 6.83M 12.83M
Adjusted Diluted Earnings per Share		 $0.00 ($62.70) ($15.60) ($38.10) ($15.96) $1.04 ($3.56)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.90M 2.03M 2.93M 3.84M 6.88M 12.83M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($62.70) ($15.60) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.73M 1.96M 3.71M 6.92M 10.48M 24.73M
Normalized Net Operating Profit after Tax (NOPAT)		 -61 -77 -28 -36 -31 -18 -36
Normalized NOPAT Margin		 -274.50% -316.57% -23.84% -143.45% -62.83% -26.66% -105.60%
Pre Tax Income Margin		 -417.65% -448.86% -26.47% -290.50% -87.28% 10.43% -134.70%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -532.76 0.00 -278.95 -56.54 -19.31 1.84 -30.72
NOPAT to Interest Expense		 -335.40 0.00 -208.81 -39.26 -13.73 -14.68 -25.67
EBIT Less CapEx to Interest Expense		 -668.29 0.00 -317.23 -59.53 -20.14 1.73 -30.73
NOPAT Less CapEx to Interest Expense		 -470.93 0.00 -247.09 -42.25 -14.56 -14.79 -25.68
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -2.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Precision BioSciences

This table displays calculated financial ratios and metrics derived from Precision BioSciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 115,070,517.00 118,935,191.00 6,916,239.00 6,925,598.00 7,233,760.00 7,671,059.00 10,481,931.00 11,088,234.00 11,786,991.00 13,256,751.00 24,726,695.00
DEI Adjusted Shares Outstanding		 3,835,684.00 3,964,506.00 6,916,239.00 6,925,598.00 7,233,760.00 7,671,059.00 10,481,931.00 11,088,234.00 11,786,991.00 13,256,751.00 24,726,695.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.11 -4.11 1.24 4.73 -2.27 -2.31 -1.96 -2.12 -1.85 1.52 -0.75
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 78.19% -33.59% 100.27% 152.15% -95.61% -90.93% -99.84% -99.96% -97.74% 5,261.13% 37,272.41%
EBITDA Growth		 18.86% -212.68% 162.48% 4,820.92% -61.57% -40.78% -404.44% -168.11% -31.22% 244.94% 17.61%
EBIT Growth		 17.88% -258.00% 140.97% 1,166.57% -41.53% -30.71% -495.21% -172.34% -28.09% 236.34% 16.33%
NOPAT Growth		 15.76% -212.60% 55.21% 1,202.41% -72.09% -66.86% -269.68% -163.42% 2.86% 171.92% 58.96%
Net Income Growth		 66.26% 42.82% 134.27% 375.41% -103.30% -8.94% -339.46% -171.82% -32.55% 213.46% 10.33%
EPS Growth		 66.26% 42.82% 125.19% 249.20% -7.14% 38.68% -230.00% -145.61% 18.22% 160.38% 66.06%
Operating Cash Flow Growth		 -179.12% 61.44% 39.67% 29.64% 74.40% -121.81% -0.37% -36.33% -158.29% 39.78% 37.35%
Free Cash Flow Firm Growth		 -213.06% -175.17% -158.22% -275.01% -51.06% -53.33% -284.89% -22.88% 64.66% 105.47% 87.63%
Invested Capital Growth		 34.64% 36.79% 18.84% 66.05% 77.51% 87.38% 90.14% 79.86% 64.15% 82.53% 56.70%
Revenue Q/Q Growth		 -33.70% -46.36% 149.84% 183.77% -98.85% 10.76% -95.45% -37.93% -27.78% 263,007.69% -68.31%
EBITDA Q/Q Growth		 -1,306.97% -23.05% 159.02% 362.04% -148.15% -7.22% -27.63% -3.33% 7.23% 218.42% -172.55%
EBIT Q/Q Growth		 -294.24% -14.67% 141.87% 463.52% -152.31% -5.90% -26.59% -3.11% 7.37% 212.72% -177.69%
NOPAT Q/Q Growth		 -295.11% -20.44% 59.83% 676.69% -161.68% -16.79% 11.00% 1.06% 5.53% 186.46% -150.79%
Net Income Q/Q Growth		 32.06% -101.62% 152.72% 281.33% -150.15% -8.04% -15.89% -14.37% 7.43% 192.47% -191.60%
EPS Q/Q Growth		 32.06% -101.62% 140.09% 174.71% -148.18% -15.56% 15.00% 3.62% 13.62% 185.33% -147.77%
Operating Cash Flow Q/Q Growth		 -9.27% 63.53% -125.35% 21.66% 60.24% -216.02% -1.98% -6.40% 24.67% 26.33% -6.11%
Free Cash Flow Firm Q/Q Growth		 -362.66% -18.24% 58.49% -35.76% -126.72% -20.01% -4.19% 56.66% 34.79% 118.56% -335.87%
Invested Capital Q/Q Growth		 14.74% -7.23% -4.86% 64.58% 43.53% 39.85% 18.02% 27.66% -0.49% 70.69% -103.22%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -76.89% -176.37% 41.66% 67.84% -2,829.69% -2,739.03% -76,906.90% -128,088.89% -164,523.08% 74.05% -169.55%
Operating Margin		 -94.23% -211.57% -23.81% 48.39% -3,693.58% -3,894.36% -76,248.28% -121,538.89% -158,976.92% 36.57% -83.73%
EBIT Margin		 -91.86% -196.36% 32.90% 65.34% -2,961.28% -2,831.35% -78,851.72% -131,044.44% -168,069.23% 72.00% -176.54%
Profit (Net Income) Margin		 -61.58% -231.44% 48.84% 65.63% -2,851.56% -2,781.35% -70,913.79% -130,666.67% -167,476.92% 58.86% -170.15%
Tax Burden Percent		 66.72% 121.17% 100.00% 99.43% 100.00% 98.95% 100.04% 100.11% 99.99% 102.29% 99.98%
Interest Burden Percent		 100.46% 97.27% 148.43% 101.02% 96.29% 99.28% 89.89% 99.61% 99.66% 79.92% 96.40%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -129.61% -154.66% -71.52% 31.21% 18.36% 19.05% -50.81% -143.89% -205.16% -61.52% -69.52%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -22.03% -48.09% 9.73% 32.96% -1,400.37% -1,313.45% -26,087.85% -1,202.99% -950.79% 16.97% -59.31%
Return on Assets (ROA)		 -14.77% -56.68% 14.44% 33.11% -1,348.49% -1,290.26% -23,461.61% -1,199.52% -947.44% 13.87% -57.17%
Return on Common Equity (ROCE)		 -129.61% -154.66% -71.52% 31.21% 18.36% 19.05% -50.81% -143.89% -205.16% -61.52% -69.52%
Return on Equity Simple (ROE_SIMPLE)		 -252.96% 0.00% -74.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.65 -10 -4.19 24 -15 -17 -15 -15 -14 13 -6.35
NOPAT Margin		 -65.96% -148.10% -23.81% 48.39% -2,585.50% -2,726.05% -53,373.79% -85,077.22% -111,283.85% 36.57% -58.61%
Net Nonoperating Expense Percent (NNEP)		 0.39% -4.25% 10.00% 7.81% -1.69% -0.44% -5.84% -11.50% -14.16% 9.54% -17.68%
Return On Investment Capital (ROIC_SIMPLE)		 - -25.25% -7.02% 24.84% -17.09% -22.10% -21.60% -27.15% -37.09% 10.91% -6.45%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 73.42% 121.33% 47.93% 17.09% 1,522.05% 1,501.10% 29,493.10% 50,705.56% 56,369.23% 21.14% 62.77%
R&D to Revenue		 120.81% 190.24% 75.88% 34.52% 2,271.53% 2,493.26% 46,855.17% 70,933.33% 102,707.69% 42.29% 120.96%
Operating Expenses to Revenue		 194.25% 311.44% 123.81% 51.99% 3,793.58% 3,964.73% 76,379.31% 121,777.78% 159,053.85% 64.70% 183.70%
Earnings before Interest and Taxes (EBIT)		 -12 -14 5.79 33 -17 -18 -23 -24 -22 25 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -12 7.33 34 -16 -17 -22 -23 -21 25 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.35 2.30 2.52 0.90 1.00 0.52 1.01 1.37 3.91 0.60 1.79
Price to Tangible Book Value (P/TBV)		 1.40 2.35 2.55 0.91 1.01 0.52 1.03 1.39 4.16 0.61 1.81
Price to Revenue (P/Rev)		 0.75 0.89 1.63 0.77 0.86 0.43 0.98 36.93 93.22 1.61 3.02
Price to Earnings (P/E)		 0.00 0.00 0.00 3.97 7.52 4.08 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 25.18% 13.30% 24.52% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.71 59.92 0.00 1.25
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.77 1.19 0.60 0.30 0.34 0.40 0.45 0.66 1.35 0.24 0.29
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.34 0.40 0.45 0.66 1.35 0.24 0.29
Financial Leverage		 -2.58 -3.48 -3.30 -2.03 -1.93 -2.14 -2.01 -1.31 -1.27 -1.08 -1.09
Leverage Ratio		 3.84 5.02 5.03 3.20 3.38 3.94 3.57 2.53 3.03 1.96 2.14
Compound Leverage Factor		 3.86 4.88 7.47 3.23 3.26 3.91 3.21 2.52 3.02 1.56 2.06
Debt to Total Capital		 43.49% 54.30% 37.64% 23.14% 25.56% 28.36% 31.16% 39.63% 57.36% 19.54% 22.76%
Short-Term Debt to Total Capital		 43.49% 54.30% 37.64% 23.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 25.56% 28.36% 31.16% 39.63% 57.36% 19.54% 22.76%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 56.51% 45.70% 62.36% 76.86% 74.44% 71.64% 68.84% 60.37% 42.64% 80.46% 77.24%
Debt to EBITDA		 -1.94 -0.64 -1.41 1.20 1.79 3.02 -1.00 -0.28 -0.27 -0.54 -0.60
Net Debt to EBITDA		 8.83 2.79 7.46 -5.58 -6.59 -9.08 2.61 0.51 0.28 2.27 2.12
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 1.79 3.02 -1.00 -0.28 -0.27 -0.54 -0.60
Debt to NOPAT		 -1.63 -0.73 -0.93 -3.08 -1.37 -0.85 -0.72 -0.35 -0.36 -0.61 -0.82
Net Debt to NOPAT		 7.41 3.18 4.90 14.30 5.07 2.57 1.88 0.64 0.37 2.57 2.90
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -1.37 -0.85 -0.72 -0.35 -0.36 -0.61 -0.82
Altman Z-Score		 -3.09 -3.44 -2.02 -1.36 -2.91 -3.96 -4.78 -6.47 -7.99 -2.65 -3.40
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.88 2.73 4.82 4.37 9.22 6.34 6.62 5.18 3.45 13.32 14.02
Quick Ratio		 2.72 2.59 4.49 4.13 8.46 5.78 6.23 4.59 2.99 12.97 13.56
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -46 -55 -23 -31 -70 -84 -87 -38 -25 4.59 -11
Operating Cash Flow to CapEx		 -5,982.64% 0.00% -73,003.85% -53,103.57% -15,158.97% -19,260.82% -29,768.75% 0.00% 0.00% 0.00% -85,264.29%
Free Cash Flow to Firm to Interest Expense		 -80.34 -94.50 -39.56 -55.06 -273.05 -214.01 -246.92 -105.83 -68.25 13.18 -34.77
Operating Cash Flow to Interest Expense		 -40.09 -14.55 -33.07 -26.55 -23.09 -47.66 -53.82 -56.62 -42.18 -32.33 -38.38
Operating Cash Flow Less CapEx to Interest Expense		 -40.76 -14.44 -33.11 -26.60 -23.25 -47.91 -54.00 -56.61 -42.14 -32.26 -38.43
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.24 0.24 0.30 0.50 0.47 0.46 0.33 0.01 0.01 0.24 0.34
Accounts Receivable Turnover		 24.75 60.12 106.15 204.05 40.61 121.59 259.60 0.00 7.27 0.00 22.51
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.43 5.37 4.82 7.80 12.21 14.57 12.78 0.38 0.25 15.18 23.11
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 14.75 6.07 3.44 1.79 8.99 3.00 1.41 0.00 50.20 0.00 16.21
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 14.75 6.07 3.44 1.79 8.99 3.00 1.41 0.00 50.20 0.00 16.21
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -71 -76 -80 -28 -16 -9.60 -7.87 -5.69 -5.72 -1.68 -3.41
Invested Capital Turnover		 -0.58 -0.50 -0.65 -1.57 -1.73 -1.60 -1.17 -0.07 -0.06 -6.08 -7.99
Increase / (Decrease) in Invested Capital		 38 44 19 55 55 66 72 23 10 7.92 4.46
Enterprise Value (EV)		 -62 -54 -25 -37 -17 -38 -8.09 5.94 42 -39 56
Market Capitalization		 39 43 94 67 65 29 50 47 65 55 136
Book Value per Share		 $0.25 $0.16 $5.38 $10.79 $8.97 $7.35 $4.71 $3.07 $1.41 $6.96 $3.08
Tangible Book Value per Share		 $0.24 $0.16 $5.32 $10.73 $8.91 $7.27 $4.65 $3.02 $1.33 $6.87 $3.03
Total Capital		 51 41 60 97 87 79 72 56 39 115 99
Total Debt		 22 22 22 22 22 22 22 22 22 22 22
Total Long-Term Debt		 0.00 0.00 0.00 0.00 22 22 22 22 22 22 22
Net Debt		 -102 -97 -119 -104 -82 -67 -58 -41 -23 -94 -80
Capital Expenditures (CapEx)		 0.39 -0.06 0.03 0.03 0.04 0.10 0.06 -0.00 -0.02 -0.03 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.63 -7.89 12 10 -2.66 -6.30 -7.51 -5.55 -8.16 -5.76 -0.25
Debt-free Net Working Capital (DFNWC)		 118 109 150 134 99 80 70 57 37 110 101
Net Working Capital (NWC)		 95 86 127 111 99 80 70 57 37 110 101
Net Nonoperating Expense (NNE)		 -0.58 5.87 -13 -8.60 1.53 0.35 5.09 8.21 7.31 -7.63 12
Net Nonoperating Obligations (NNO)		 -100 -95 -117 -103 -81 -66 -57 -40 -22 -94 -80
Total Depreciation and Amortization (D&A)		 1.96 1.41 1.54 1.24 0.76 0.59 0.56 0.53 0.46 0.70 0.76
Debt-free, Cash-free Net Working Capital to Revenue		 -8.86% -16.20% 21.18% 11.41% -3.54% -9.18% -14.69% -440.21% -1,169.20% -16.80% -0.55%
Debt-free Net Working Capital to Revenue		 224.91% 223.25% 260.64% 152.41% 131.22% 116.47% 136.31% 4,495.72% 5,259.17% 320.53% 223.94%
Net Working Capital to Revenue		 182.14% 177.26% 221.60% 126.74% 131.22% 116.47% 136.31% 4,495.72% 5,259.17% 320.53% 223.94%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.10) ($127.20) $1.70 $4.70 ($2.25) ($2.60) ($2.21) ($2.13) ($1.84) $1.57 ($0.75)
Adjusted Weighted Average Basic Shares Outstanding		 3.84M 128.05K 5.06M 6.97M 7.29M 6.83M 9.29M 11.05M 11.82M 12.83M 24.63M
Adjusted Diluted Earnings per Share		 ($2.10) ($127.20) $1.70 $4.67 ($2.25) ($2.60) ($2.21) ($2.13) ($1.84) $1.57 ($0.75)
Adjusted Weighted Average Diluted Shares Outstanding		 3.84M 128.05K 5.06M 7.01M 7.29M 6.88M 9.29M 11.05M 11.82M 12.83M 24.63M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($127.20) $0.00 $0.00 $0.00 ($2.60) $0.00 $0.00 $0.00 $1.57 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.96M 230.54K 6.93M 7.23M 7.67M 10.48M 11.09M 11.79M 13.26M 24.73M 25.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.65 -10 -2.93 17 -15 -17 -15 -15 -14 8.76 -6.36
Normalized NOPAT Margin		 -65.95% -148.10% -16.67% 34.14% -2,585.50% -2,726.05% -53,352.07% -84,980.00% -111,300.00% 25.60% -58.64%
Pre Tax Income Margin		 -92.29% -191.01% 48.84% 66.01% -2,851.56% -2,810.97% -70,882.76% -130,527.78% -167,500.00% 57.55% -170.19%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -20.92 -23.87 10.08 58.22 -66.63 -46.08 -64.60 -65.89 -60.36 70.77 -61.52
NOPAT to Interest Expense		 -15.02 -18.00 -7.29 43.12 -58.17 -44.37 -43.72 -42.78 -39.96 35.94 -20.43
EBIT Less CapEx to Interest Expense		 -21.59 -23.76 10.03 58.17 -66.78 -46.33 -64.78 -65.88 -60.31 70.84 -61.57
NOPAT Less CapEx to Interest Expense		 -15.69 -17.89 -7.34 43.07 -58.33 -44.62 -43.91 -42.77 -39.92 36.01 -20.47
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Precision BioSciences (NASDAQ: DTIL) showed a much stronger balance sheet in Q1 2026, but the operating story remains challenging. The company ended the quarter with a sizable cash position and enough liquidity to fund operations in the near term, yet it continued to post meaningful operating losses and negative operating cash flow. For retail investors, that means the stock has a stronger financial cushion than it did a year ago, but the business is still burning cash faster than it is generating it.

Key takeaways from the last several quarters:

  • Cash and equivalents rose sharply to $99.4 million in Q1 2026, up from $44.9 million in Q3 2025 and well above the $77.2 million reported in Q1 2025. That gives the company more breathing room.
  • Total current assets climbed to $108.7 million, supported by cash, short-term investments, and prepaid assets, improving near-term liquidity.
  • Common equity increased to $76.1 million in Q1 2026, versus $16.6 million in Q3 2025, reflecting balance sheet strengthening after financing activity.
  • Quarterly revenue in Q1 2026 jumped to $10.8 million from just $13,000 in Q3 2025 and $29,000 in Q1 2025. That is a meaningful improvement in top-line generation, even if it may not yet be durable.
  • Financing activity added $745,000 of cash in Q1 2026, indicating the company still has access to external capital when needed.
  • Long-term debt was $22.4 million in Q1 2026, roughly in line with prior quarters, so leverage is present but not worsening dramatically.
  • R&D spending remained substantial at $13.1 million in Q1 2026, which supports pipeline development but also keeps the company in a cash-burning mode.
  • Operating loss was $9.1 million in Q1 2026, showing the core business still is not profitable despite higher revenue.
  • Net loss widened to $18.4 million in Q1 2026, and adjusted for financing and non-operating items, profitability remains far off.
  • Operating cash flow was negative $11.9 million in Q1 2026, meaning the company continued to consume cash from day-to-day operations.

Longer-term trend: DTIL’s financial profile has improved on the liquidity side, especially compared with the tighter periods seen in 2025. However, the income statement still shows a biotech company dependent on financing and non-operating items rather than recurring operating profitability. Revenue is highly uneven quarter to quarter, and while Q1 2026 showed a notable spike, the company has not yet established a stable growth pattern.

Bottom line: Precision BioSciences looks better capitalized than it did several quarters ago, which lowers immediate balance sheet risk. But investors should still focus on two things: whether revenue can become repeatable, and whether operating losses can narrow without requiring continued dilution or debt financing.

07/17/26 05:02 PM ETAI Generated. May Contain Errors.

Precision BioSciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Precision BioSciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Precision BioSciences' net income appears to be on a downward trend, with a most recent value of -$45.72 million in 2025, falling from -$98.55 million in 2019. The previous period was $7.17 million in 2024. View Precision BioSciences' forecast to see where analysts expect Precision BioSciences to go next.

Precision BioSciences' total operating income in 2025 was -$52.15 million, based on the following breakdown:
  • Total Gross Profit: $34.26 million
  • Total Operating Expenses: $86.87 million

Over the last 6 years, Precision BioSciences' total revenue changed from $22.24 million in 2019 to $34.26 million in 2025, a change of 54.1%.

Precision BioSciences' total liabilities were at $62.17 million at the end of 2025, a 22.3% decrease from 2024, and a 37.0% decrease since 2018.

In the past 7 years, Precision BioSciences' cash and equivalents has ranged from $85.90 million in 2024 to $189.58 million in 2022, and is currently $110.82 million as of their latest financial filing in 2025.

Over the last 6 years, Precision BioSciences' book value per share changed from 2.72 in 2019 to 6.96 in 2025, a change of 155.5%.


Related Companies

Financial statements for NASDAQ:DTIL last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel